Abstract:Purpose: Myelodysplastic syndromes (MDS), is characterized by clinical heterogeneity and varying prognoses. Reliable prognostic models are essential to stratify MDS patients and optimize clinical management. Although incorporating molecular information into MDS prognostic models improves their predictive ability, limitations of next-generation sequencing panels and potential heterogeneity among MDS patients with different karyotypes hinder their clinical translation. Methods: In total, 237 normal karyotype (NK) MDS patients from the First Affiliated Hospital of Zhejiang University School of Medicine were used as the derivation set to investigate the molecular frequency and prognostic spectrum. A parsimonious molecular-clinical model was developed with overall survival (OS) as the endpoint and compared with other models using the concordance index as the primary evaluation index. An external independent validation set from the International Working Group for Prognosis in MDS cohort(691 NK MDS patients) was used to evaluate the model generalization ability. Results: In NK MDS, the gene mutation frequency spectrum is similar to the overall MDS population, the differences mainly lie in the prognostic spectrum. Genes such as TP53, previously associated with MDS prognoses have lost their prognostic value. Therefore, a seven-parameter molecular-clinical prognostic model called the Molecular Prognostic Scoring System for NK MDS (NK-PSS-M) was developed based on a specific molecular prognostic spectrum of NK MDS. The model includes age, hemoglobin, platelet count, blast percentage, CEBPA, RUNX1, and U2AF1. The NK-PSS-M model allows for personalized risk assessment based on patient characteristics, with higher scores indicating a greater risk and poorer prognosis. In addition, we developed a five-class classification system based on these scores, which differentiates patients across risk categories and predicts outcomes, such as OS and LFS(Figure 1 A and B). The performance of NK-PSS-M was comparable to that of the Molecular International Prognostic Scoring System(IPSS-M), and it significantly outperformed IPSS-R and other molecular prediction models based on it. The above results were confirmed in the external independent validation cohort(Figure 1C). Our transcriptomics analysis revealed that the low-risk group defined by NK-PSS-M demonstrated significant activation of the inflammatory pathway, and immune activation, which is consistent with the current understanding of the immunological landscape of MDS. Conclusion: The NK-PSS-M model improved the risk stratification of non-molecular models and provided a reliable alternative to the IPSS-M. In addition, we demonstrated the molecular heterogeneity of MDS across different cytogenetics and emphasized the importance of developing cytogenetics-specific prognostic models.

Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

The Molecular Prognostic Scoring System for Normal Karyotype Myelodysplastic Syndromes

A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients with SF3B1 Mutation.

Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome

A Multifactorial Risk Scoring System for the Prediction of Early Relapse in CMML Patients with Allo-Hsct: a Nationwide Representative Multicenter Study

[The Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation from Human Leukocyte Antigen-Identical Siblings in 95 Patients with Myelodysplastic Syndrome].

Haplo-Identical Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Similar Survival in Comparison with HLA-Identical Siblings: Multi-Center, Prospective Study

The Clinical Outcomes of Haploidentical Stem Cell Transplantation (Haplo-Hsct) for Patients with Therapy-Related Myelodysplastic Syndrome: Comparable to De Novo Myelodysplastic Syndrome

Development and validation of a mortality predicting scoring system for severe aplastic anaemia patients receiving haploidentical allogeneic transplantation

The Clinical Analysis of Haploidentical Stem Cell Transplantation in Myelodysplastic Syndrome-Associated Acute Myeloid Leukemia

IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms

Molecular Prognostication for Transplant Decision Making of Patients with Myelodysplastic Syndromes: A Retrospective Single-Center Study

Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation.

Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome

HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

A novel prognostic scoring system for AML patients undergoing allogeneic hematopoietic stem cell transplantation with real world validation

Comparison of clinical outcomes between peripheral blood stem cells and peripheral blood stem cells plus bone marrow in myelodysplastic syndrome patients with haploidentical transplantation

[Analysis of Clinical Efficacy and Prognosis in 83 Cases Receiving Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies].

Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation.

[Allogenic Stem Cell Transplantation from Genotypically HLA-identical Siblings for 30 Patients with Myelodysplastic Syndromes].